

CERTIFICATE OF ANALYSIS

SS-31 (Elamipretide) - 10 mg


Mitochondria-targeting tetrapeptide - D-Arg-Dmt-Lys-Phe-NH2

Material	SS-31 (Elamipretide)	Client	novumpeptides.com	Received	2026-08-18 at 2-8 C
Batch / lot	PEP-42-9HU	Label claim	10 mg	Analysed	2026-08-19 to 2026-08-20

TEST RESULTS

ATTRIBUTE	RESULT	SPECIFICATION	METHOD	VERDICT
Identity	Conforms	Matches reference	MA-MS-014 / LC-HRMS	Conforms
Purity (area %)	99.23%	>= 99.00%	MA-UHPLC-031 / UV 214	Pass
Largest single impurity	0.22%	<= 0.50%	MA-UHPLC-031 / UV 214	Pass
Total related substances	0.77%	<= 1.00%	MA-UHPLC-031 / UV 214	Pass
SS-31 (Elamipretide) per vial	9.99 mg	9.00-11.00 mg	MA-ASSAY-011 / UHPLC-UV	Pass
Water content	4.55%	<= 8.00%	MA-KF-004 / Karl Fischer	Pass
Residual acetonitrile	210 ppm	<= 410 ppm	MA-GC-006 / HS-GC-FID	Pass
Residual TFA	0.10%	<= 1.00%	MA-IC-003 / ion chromatography	Pass

RP-UHPLC processed trace, UV detection



Record NB8U9HU-PEP-01; duplicate independent preparations. System suitability met retention-time and resolution criteria; blank response was below threshold.

Related species > 0.05%

deletion sequence	0.22%
insertion sequence	0.17%
diastereomeric variant	0.12%
N-terminal variant	0.09%
C-terminal variant	0.07%
unresolved peaks	0.10%

Related species were assigned by orthogonal reference comparison and mass-spectrometric or chromatographic evidence. Mean area percentages; reporting threshold 0.05%.

Conclusion

Identity and quality attributes met the stated criteria. Mean SS-31 (Elamipretide) content was 9.99 mg/vial and chromatographic purity was 99.23%.

Identity was established by LC-HRMS against a qualified reference; content and related substances were assessed independently.

Analytical review

Ines Abadi I. Abadi

Quality review

Marcus Oyelaran

Approval date: 2026-08-21 M. Oyelaran

Decision rule: guarded acceptance; reported outcomes account for method uncertainty and remain within the stated project specifications.